HESKA CORP: management transactions · United States · SEC (Form 4)

About HESKA CORP

Heska Corp. (ticker HSKA) was a United States animal-health company best known for veterinary diagnostics and specialty products for companion animals. Historically listed on the NASDAQ market in the United States, Heska was acquired by Mars, Inc., with the transaction announced in April 2023 and completed on June 13, 2023. As a result, Heska became part of Mars Petcare’s Science & Diagnostics division, which materially expanded its scale and global reach in veterinary diagnostics. The company was founded in 1988 and built its franchise around a focused but strategically attractive niche: providing veterinarians with tools for clinical testing, monitoring, and workflow support for dogs and cats. ([mars.com](https://www.mars.com/news-and-stories/press-releases-statements/mars-to-acquire-heska-global-provider-advanced-veterinary-solutions?utm_source=openai)) Heska’s business model was centered on three core lines: point-of-care diagnostic instruments, recurring consumables tied to those instruments, and software/informatics solutions for veterinary practices. Its portfolio included in-clinic laboratory analyzers, digital imaging products, rapid diagnostic tests, data services, and allergy/immunotherapy offerings. The company also broadened its software capabilities in Europe through the 2022 acquisition of VetZ GmbH, a veterinary practice information management software provider. That combination of hardware, consumables, and software gave Heska a more integrated profile than a pure-play device manufacturer and supported recurring revenue opportunities through consumable usage and service relationships. ([nasdaq.com](https://www.nasdaq.com/press-release/heska-to-host-virtual-2022-investor-day-on-may-17-2022-2022-04-29?utm_source=openai)) Before the Mars transaction, Heska operated as a specialized player in animal health with North American and international exposure. Its headquarters were in Loveland, Colorado, United States. Competitive positioning was built around a “full-stack” offering for veterinary clinics: diagnostics, imaging, informatics, and specialty products, with a strong emphasis on companion-animal care. In structural terms, that positioned Heska in a favorable end-market, as veterinary clinics have increasingly invested in more advanced in-house testing and digital workflows, while pet healthcare spending has continued to rise over time. ([sec.place](https://sec.place/companies/heska-corp-1038133?utm_source=openai)) The key recent corporate event is the Mars acquisition. Mars and Heska announced a definitive agreement on April 3, 2023, under which Mars agreed to acquire Heska for $120.00 per share. The deal closed on June 13, 2023, and Mars said the combination would broaden access to diagnostics and technology while accelerating R&D and innovation. For investors, the practical takeaway is that HSKA is no longer a conventional standalone U.S.-listed equity on NASDAQ, but its legacy remains that of a U.S.-based veterinary diagnostics specialist with a strong technology-led product mix and a meaningful role in the global companion-animal health market. ([mars.com](https://www.mars.com/news-and-stories/press-releases-statements/mars-to-acquire-heska-global-provider-advanced-veterinary-solutions?utm_source=openai))